China Medical Technologies has developed two proprietary molecular diagnostic kits that detect abnormalities in epidermal growth factor receptor (EGFR) among patients with non-small cell lung cancer (NSCLC). EGFR abnormalities are important biomarkers for the biologic cancer drugs Iressa from AstraZeneca and Tarceva from Genentech. China Medical expects to launch the new kits for its hospital customers in January 2009. More details...

Stock Symbols: (NSDQ: CMED) (NYSE: AZN) (NYSE: DNA)